Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06303739 · ClinicalTrials.gov registry record · Phase 3
Psilocybin-Assisted Therapy in Treatment-Resistant Depression
A Phase 3 study of Treatment-Resistant Depression and Refractory Depression, sponsored by University of North Carolina, Chapel Hill.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT06303739 is a Phase 3 study of Treatment-Resistant Depression and Refractory Depression that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 23 participants, below the 373-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06303739, a Phase 3 study of Treatment-Resistant Depression and Refractory Depression, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to test how well psilocybin-assisted therapy works in treating people with depression. The main questions this study aims to answer are: * Does psilocybin with assisted therapy help improve symptoms for people with depression? * How long do the effects of this treatment last? Participants will: * Take part in a couple of screening and preparation visits. * Be given psilocybin in one or two treatment sessions. * Attend a series of follow-up sessions over the following year. * Complete forms and surveys to test how their symptoms have changed and what they thought of their experience. Researchers will also compare whether one treatment or two treatments help improve symptoms more for participants.
Conditions Studied
Interventions
- DRUG psilocybin
Study Locations (1)
North Carolina
- UNC Chapel Hill Medical Center - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2024-04-19 |
| Est. Completion | 2027-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06303739
The ClinicalTrials.gov registry entry for NCT06303739 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 373-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (94% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 1 intervention - of which psilocybin is the first listed.
NCT06303739 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06303739 about?
NCT06303739 is a clinical study titled "Psilocybin-Assisted Therapy in Treatment-Resistant Depression". The goal of this clinical trial is to test how well psilocybin-assisted therapy works in treating people with depression. The main questions this study aims to answer are: * Does psilocybin with assisted therapy help improve symptoms for people with depression? * How long do the effects of this tre...
What is the current status of trial NCT06303739?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 23 participants. The study started on 2024-04-19. Estimated completion is 2027-06.
What conditions does trial NCT06303739 study?
This clinical trial studies the following conditions: Treatment-Resistant Depression, Refractory Depression.
What interventions are being tested in trial NCT06303739?
The interventions under investigation include: psilocybin (DRUG).
Who is sponsoring clinical trial NCT06303739?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06303739 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Treatment-Resistant Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Biomarker-guided rTMS for Treatment Resistant Depression
RECRUITING · Phase 3
-
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
ACTIVE NOT RECRUITING · Phase 3
-
A Study in Relapse Prevention of Treatment-Resistant Depression
COMPLETED · Phase 3
-
Open-Label Safety Study of AXS-05 in Subjects With Depression
COMPLETED · Phase 3
-
Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression
RECRUITING · NA
Explore more on PlainTrial
Treatment-Resistant Depression
All registered trials for this condition
Refractory Depression
All registered trials for this condition
North Carolina
All trials with a study site in North Carolina
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.